Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 12;13(1):9555.
doi: 10.1038/s41598-023-36604-4.

Disparity in the use of Alzheimer's disease treatment in Southern Brazil

Maisa De Marco  1 , Ana Laura Brandi  2 , Andrei Bieger  3 , Bárbara Krug  4 , Analuiza Camozzato  5 , Paulo D Picon  6 , Marcia Lorena Fagundes Chaves  6   7 , Raphael Machado Castilhos  8   9
Affiliations
Review

Disparity in the use of Alzheimer's disease treatment in Southern Brazil

Maisa De Marco et al. Sci Rep. .

Erratum in

Abstract

Alzheimer's disease (AD) treatment is freely available in the Brazilian public health system. However, the prescription pattern and its associated factors have been poorly studied in our country. We reviewed all granted requests for AD treatment in the public health system in October 2021 in the Rio Grande do Sul (RS) state, Southern Brazil. We performed a spatial autocorrelation analysis with the population-adjusted patients receiving any AD medication as the outcome and correlated it with several socioeconomic variables. 2382 patients with AD were being treated during the period analyzed. The distribution of the outcome variable was not random (Moran's I 0.17562, P <.0001), with the most developed regions having a higher number of patients/100,000 receiving any AD medication. We show that although AD medications are available through the public health system, there is a clear disparity between regions of RS state. Factors related to socioeconomic development partly explain this finding.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Choropleth map of spatial distribution of patients/100,000 inhabitants receiving Alzheimer's disease medications in the state of Rio Grande do Sul, Brazil. Maps created with R software, version 4.2.2, and Adobe Illustrator, version 27.5.
Figure 2
Figure 2
Moran scatter plot, showing the correlation between the patients/100,000 variable and its spatial lag.
Figure 3
Figure 3
Scatter plots between patients/100,000 inhabitants and socioeconomic variables.
See this image and copyright information in PMC

References

    1. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019. Lancet Public Health. (2022) 7:e105–25. - PMC - PubMed
    1. Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, et al. Alzheimer’s disease. Lancet. 2021;397:1577–90. doi: 10.1016/S0140-6736(20)32205-4. - DOI - PMC - PubMed
    1. Ehret MJ, Chamberlin KW. Current practices in the treatment of alzheimer disease: Where is the evidence after the phase III trials? Clin Ther. 2015;37:1604–16. doi: 10.1016/j.clinthera.2015.05.510. - DOI - PubMed
    1. Costa, A.F., Picon, P.D., Amaral, K.M., Chaves, M.L.F. Protocolo clínicos e diretrizes terapêuticas. [cited 2023 Jan 19]. Available from: https://bvsms.saude.gov.br/bvs/publicacoes/protocolos_clinicos_diretrize...
    1. Protocolos Clínicos e Diretrizes Terapêuticas. [cited 2022 Nov 23]. Available from: https://www.gov.br/saude/pt-br/assuntos/pcdt/arquivos/2020/portaria-conj...

Publication types